Tags: Inflammation


$3.2 Million in New Funding Focused on Biomarkers and Moving Toward New Therapies

These recent investments reflect the ADDF's commitment to advancing tools for early detection, with an emphasis on exploring the different pathologies associated with aging.


$7.1 Million in New Funding Illustrates the ADDF's Strong Support of a Diverse Pipeline

The ADDF announces $7.1 million in new investments, which reflect our strategy to advance drug discovery and clinical trials, including the development of biomarkers and prevention methods.


$2.3 Million in New Funding Focused on Novel Biomarkers and Treatments

The Alzheimer's Drug Discovery Foundation (ADDF) announces funding for a novel biomarker and two Phase I clinical studies.


New Investments Fund Research Ranging from Novel Treatments for Postoperative Cognitive Dysfunction

The Alzheimer's Drug Discovery Foundation (ADDF) announces seven new investments, including clinical trials, novel drug programs, and a prevention program, which reflects the comprehensive nature of the ADDF's funding strategy.


Partnership with FNIH Will Drive New Biomarkers for Alzheimer's

The ADDF has joined an initiative from the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium that will improve diagnosis and the development of targeted therapies for Alzheimer's disease. 


$1.8 Million in New Funding Supports Clinical Stage Treatments

The ADDF announces nearly $1.8 million in new funding, which reflects our commitment to advancing drugs in or near human clinical trials.


Three New Grants Keep Promising Programs Forging Ahead

The Alzheimer’s Drug Discovery Foundation (ADDF) announces three new investments, all of which are for programs that the ADDF previously funded.


Combination Therapy: The Right Approach for Alzheimer’s

Learn why combination therapy holds such promise for treating Alzheimer's disease, and why Amylyx's drug is the first such therapy we are funding.


Innovative Alzheimer's Combination Therapy Trial Supported by New Joint Funding Initiative

We are jointly funding a new combination therapy clinical trial for Alzheimer’s disease to be conducted by Amylyx Pharmaceuticals.


18th Annual Conference on Alzheimer's Drug Discovery Showcases Non-Amyloid Research

Nearly 200 academic and industry researchers came together to share updates on innovative preclinical and clinical-stage Alzheimer’s disease research at the 18th Annual Conference on Alzheimer's Drug Discovery.